



**YES!** Beat Liver Tumors  
Newsletter

877-937-7478

## A MESSAGE FROM JOANNA

**We are coming to the last days of 2021 and I, personally, am looking forward to a new year. It is with great anticipation that I am wanting the pandemic to end. I have spent more time in the hospital than out the past month and am more thankful to YES than ever before. The support that all of you have provided to me is more than anything I could have ever imagined.**



**As we end 2021, please remember that year end donations will go far in helping other patients that are in a situation like mine that feel hopeless. I have experienced firsthand the support, resources, and hope that YES offers. I have never met anyone like the instant FRIENDS that I have made since finding Say YES to Hope.**

**In 2022, I hope that in person activities can happen once again. I know that you will see the resources, awareness, support and HOPE that are provided through YES. Let's rock into 2022!**

**Remember, your donations make deLIVERing Hope possible. Please consider making a recurring monthly donation. Just \$10.00 will provide a Survivor Bag!**



**THANK YOU TO ALL THE SPONSORS WHO MADE THE 1<sup>ST</sup> ANNUAL RIDE FOR HOPE A HUGE SUCCESS!!**

The rain was kind enough to hold off until the ride was over and all riders were safe and back to base. The BBQ and potato salad were delicious and our entertainers were the best. Claude Gray, Red Leone, Pamela King, and Clay Thrash were phenomenal!

Huge thanks to all those who donated silent auction items. All in all, we raised:



## Say YES to Hope Patient Dinner If Cancer Spreads to the Liver, Where do You Turn?

Twenty patients recently attended an educational dinner held in the Houston, Texas medical district. The patients and their family members learned about treatment options available for metastatic liver tumors. Dr. Paulo Cen, Medical Oncologist spoke about the importance of multidisciplinary care and how medical oncology can work with the various other disciplines like surgery, radiology, and interventional radiology to provide patients with the best outcome. Dr. Ahmed Kamel Abdel Aal, Interventional Radiologist, discussed the way that his field communicates with medical oncology and the targeted liver tumor treatments that he performs including microwave ablation, cryoablation, chemoembolization, and radioembolization. All attendees received a survivor bag and enjoyed the first in person patient event for YES since the beginning of the pandemic.

If cancer spreads, where do you turn?  
Discover options, resources, support and



Please join us for this free informational seminar.

Thursday, October 14, 2021  
7:00pm – 9:00pm  
Seasons 52  
4410 Westheimer Rd C-1

To register or for more information visit  
[www.SayYesToHope.org](http://www.SayYesToHope.org) or call 877-937-7478.



Who should attend? Anyone affected by liver tumors!

#### AGENDA

- 7:00pm Welcome  
Suzanne Lindley  
Co-Founder, Say YES to Hope
- 7:15pm  Putao Cen, MD  
Medical Oncologist
- 7:30pm  Ahmed Kamel Abdel Aal, MD, PhD, FSIR  
Interventional Radiologist
- 7:45pm Dinner and Q and A




#### There is definitely HOPE!

Meet 23 year Stage 4 Colon Cancer Survivor, Suzanne Lindley, Co-Founder of Say YES to Hope. Hear her inspiring story of survival!



YES  
2000 Westheimer  
Houston, Texas 77058  
877-937-7478



October 28, 2021 Incredible ZOOM meeting with Midwest Medical Professionals discussing YES and the importance of multidisciplinary team with Heidi Sipe and Kathleen Mary.



### November 2, 2021 MIAMI ONS DINNER

Miami ONS Dinner meeting was sponsored by Sirtex Medical. David Shadeed, RN presented about the delivery and benefit of radioembolization. YES discussed the importance of a multidisciplinary treatment team for patients, the impact of nurse navigators for patients, and the support, resources, and HOPE that YES provides to patients who are affected by cancers of the liver.

# Keep On Keepin' On Corner

By Tami Thennis

“Your hardest times often lead to the greatest moments of your life. Keep going. Tough situations build strong people in the end.”

- Roy T. Bennett

You can, you should, and if you're brave enough to start, you will.”

- Stephen King

“The first step is that you have to say that you can.”

- Will Smith

“Positive anything is better than negative nothing.”

- Elbert Hubbard

-

“Problems are not stop signs, they are guidelines.”

- Robert Schuller

“A little progress each day brings big results.”

- Unknown

“Try to be a rainbow in someone's cloud.”

- Maya Angelou

“Live to the fullest and focus on the positive.”

- Matt Cameron

“Hope dances in the shadows and sings in the rain.”

- Suzanne Lindley

## SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

*The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.*

## Imfinzi/tremelimumab combo scores AstraZeneca another OS win — this time in liver cancer

Dubbed HIMALAYA, the trial delivered the second set of positive results for the treme/Imfinzi combo after years of failure.

The design of the dosing regimen may have played a role, suggested Ghassan Abou-Alfa, attending physician at Memorial Sloan Kettering Cancer Center and principal investigator.

“HIMALAYA is the first Phase III trial to add a novel single priming dose of an anti-CTLA4 antibody to another checkpoint inhibitor, durvalumab,” he said in a statement. “This serves to boost the patient's own immune system against their liver cancer, aiming to maximise long-term survival with minimal side effects.”

HIMALAYA, on the other hand, tested a regimen AstraZeneca is calling STRIDE — short for single tremelimumab regulator interval durvalumab. It reported a favorable safety profile and noted that “the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity.”

Susan Galbraith, AstraZeneca's EVP of oncology R&D, noted that patients with unresectable liver cancer have limited first-line treatment options and poor prognoses.

“Inhibition of CTLA-4 has shown the ability to drive benefit particularly in the tail of the survival curve in several settings,” she added.

# NEWS TO USE



## Toll Free SURVIVOR Line:

Our toll free Survivor Line provides an outlet for patients and concerned others. It is a place to access resources, advocacy, and support regarding treatment options for cancers of the liver. You can also receive information on how to become a part of our survivor support program, "FRIENDS for the Journey."

**Call 1-877-937-7478**



We offer a unique survivor mentoring program called "FRIENDS for the Journey" that matches survivors, caregivers, family and friends who are going through a similar experience. Comparing options is a vital way to maintain a positive outlook. FRIENDS can communicate via phone, email, snail mail, or in person.



## YES! You Can Too

791 Arnold Paul \* Canton, Texas 75103

877-937-7478

[info@beatliver Tumors.org](mailto:info@beatliver Tumors.org)

[www.beatliver Tumors.org](http://www.beatliver Tumors.org)